The mission of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. As a matrixed, consortium cancer center, SKCC leverages the intellectual strength of discoveries of members at Thomas Jefferson University (TJU), Drexel University (DU) Schools of Medicine and Public Health, and Lankenau Institute for Medical Research (LIMR). Expertise is clustered into five major Research Programs, two of which are Discipline-Based Programs and three of which are Disease-Oriented Programs. A notable feature of SKCC Programs is that each is comprised of highly integrated basic, clinical, and population researchers, working together on research areas that address the cancer-associated needs of the catchment area. This is an intentional structure that further blossomed under the guidance of new SKCC leadership and the revitalized External Advisory Board (EAB). Given the health research and care focus of the parent university (TJU), this mechanism of Program integration mirrors the strong translational focus and interdisciplinary nature of the organization. SKCC utilizes the TIPS (Transdisciplinary Integration of Population Science) mechanism as a highly specialized, cross-cutting organizational structure that has the benefit of allowing population scientists to remain programmatically integrated into Programs with basic and clinical researchers, as well as providing a platform for cultivating new population oriented strategies that can be deployed across all Programs. Thematic working groups also exist that link subspecialties across Programs, in addition to Shared Resources that provide exceptional expertise, services, and technologies required for leading edge investigation and high scientific impact. Under the new Director, Dr. Knudsen (appointed January 2015), SKCC sharpened focus on addressing catchment area needs, nurtured transdisciplinary research, expanded research capabilities, extended outreach and clinical research into the community, and enhanced the pace of bench-to-bedside discovery. The roadmap for the SKCC mission is paved by a strategic plan deemed IMPACT, developed by Dr. Knudsen and highly engaged SKCC Leaders. Under Dr. Knudsen?s leadership, SKCC increased: membership, the pace and breadth of impactful discovery, bench-to-bedside translation, clinical trial activity, cancer-focused funding, capacity to address the cancer needs of the catchment area, and the overall impact of the Center. Current aims are to: 1) Discover the molecular basis of cancer development & progression in diverse populations through integration of basic, population, and clinical research; 2) Develop knowledge into effective new prevention, detection, and treatment strategies for cancer, emphasizing catchment area needs; 3) Disseminate through patient education and training of laboratory-based, population, and clinical scientists; 4) Deliver and enhance access to the most advanced cancer care.

Public Health Relevance

The overarching goal of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. SKCC is nucleated at Thomas Jefferson University (TJU) and enriched by fully integrated research consortium partners from Drexel University (DU)'s School of Medicine and School of Public Health and the Lankenau Institute for Medical Research (LIMR); building on these strengths, SKCC focuses on addressing catchment area needs through nurturing transdisciplinary research, expanding innovative research capabilities, extending outreach and clinical research into the community, and enhancing the pace of bench-to-bedside discovery.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA056036-19S1
Application #
9759284
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ptak, Krzysztof
Project Start
1995-06-22
Project End
2023-05-31
Budget Start
2018-06-18
Budget End
2019-05-31
Support Year
19
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Mikkilineni, Lekha; Whitaker-Menezes, Diana; Domingo-Vidal, Marina et al. (2017) Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. Semin Oncol 44:218-225
Wirblich, Christoph; Coleman, Christopher M; Kurup, Drishya et al. (2017) One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. J Virol 91:
Weinberg, David S; Lin, Jieru E; Foster, Nathan R et al. (2017) Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prev Res (Phila) 10:345-354
Monti, Daniel; Sotgia, Federica; Whitaker-Menezes, Diana et al. (2017) Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer. Semin Oncol 44:226-232
Curry, Joseph; Johnson, Jennifer; Tassone, Patrick et al. (2017) Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. Laryngoscope 127:1808-1815
Mitra, Ramkrishna; Chen, Xi; Greenawalt, Evan J et al. (2017) Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun 8:1604
Paolillo, Carmela; Mu, Zhaomei; Rossi, Giovanna et al. (2017) Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. Clin Cancer Res 23:6086-6093
Overmiller, Andrew M; Pierluissi, Jennifer A; Wermuth, Peter J et al. (2017) Desmoglein 2 modulates extracellular vesicle release from squamous cell carcinoma keratinocytes. FASEB J 31:3412-3424
Cheng, Hanyin; Chua, Vivian; Liao, Connie et al. (2017) Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Mol Cancer Ther 16:516-528
Jiang, Wei; Dulaimi, Essel; Devarajan, Karthik et al. (2017) Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. Oncotarget 8:37423-37434

Showing the most recent 10 out of 777 publications